reboxetine has been researched along with yohimbine in 3 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (yohimbine) | Trials (yohimbine) | Recent Studies (post-2010) (yohimbine) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 5,893 | 253 | 532 |
| Protein | Taxonomy | reboxetine (IC50) | yohimbine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0353 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.02 | |
| D(2) dopamine receptor | Homo sapiens (human) | 2.06 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0428 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0466 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.126 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.013 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.126 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.074 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.689 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I | 1 |
| Conrad, KL; Davis, AR; Javitch, JA; Lindsley, CW; Matthies, HJ; Saleh, SA; Sen, N; Sheffler, DJ; Shields, AD; Silberman, Y; Winder, DG | 1 |
| Duarte, ID; Guzzo, LS; Resende, LC; Romero, TR | 1 |
3 other study(ies) available for reboxetine and yohimbine
| Article | Year |
|---|---|
Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amines; Animals; Anticonvulsants; Antidepressive Agents; Cyclohexanecarboxylic Acids; Cyclohexanols; Desipramine; Gabapentin; gamma-Aminobutyric Acid; Male; Mice; Mice, Transgenic; Morpholines; Pain; Pain Threshold; Propanolamines; Reboxetine; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-2; Sciatic Nerve; Venlafaxine Hydrochloride; Yohimbine | 2009 |
Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine-independent processes.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Behavior, Animal; Cocaine; Drug-Seeking Behavior; Extinction, Psychological; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Neuropeptides; Neurotransmitter Agents; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Orexin Receptors; Orexins; Patch-Clamp Techniques; Reboxetine; Receptors, Adrenergic, alpha-2; Receptors, Corticotropin-Releasing Hormone; Receptors, Neuropeptide; Reward; Septal Nuclei; Synaptic Transmission; Yohimbine | 2012 |
CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Dinoprostone; Endocannabinoids; Ethanolamines; Male; Morpholines; Norepinephrine; Pain Measurement; Palmitic Acids; Peripheral Nerves; Polyunsaturated Alkamides; Prazosin; Propranolol; Rats; Rats, Wistar; Reboxetine; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sympathetic Nervous System; Yohimbine | 2013 |